|

anti-CD19 CAR-T cells Clinical Trials

5 actively recruiting trials across 2 locations

Also known as: Axi-cel, CD19-directed Chimeric Antigen Receptor T-Cell (CAR T-cell) therapy, CD19-directed chimeric antigen receptor (CAR) T-cell therapy, Experimental CAR-T cells, Other commercial CAR-T cells +1 more

Pipeline

Early 1: 1Phase 1: 2Phase 2: 1Phase 1/2: 1

Top Sponsors

  • University of Utah1
  • Shanghai Tongji Hospital, Tongji University School of Medicine1
  • KK Women's and Children's Hospital1
  • Chinese PLA General Hospital1
  • C. Babis Andreadis1

Indications

  • Cancer5
  • Diffuse Large B-Cell Lymphoma2
  • Transformed Lymphoma1
  • B-cell Malignancies1
  • CAR1

Other3 trials

Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
Early 1
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
Phase 2
Chidamide Bridging for CAR-T Therapy
Phase 1/2

San Francisco, California1 trial

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco

Phase 1

Salt Lake City, Utah1 trial

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

Huntsman Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.